Completion of patient screening in phase III trial of roluperidone to treat negative symptoms in schizophrenia.- Minerva Neurosciences
Related news and insights
AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy.
Laboratorios Farmacéuticos Rovi, S.A. has announced that the European Commission has authorised the marketing of Okedi (Risperidone ISM) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.